Zobrazeno 1 - 7
of 7
pro vyhledávání: '"329"'
Autor:
Romain Guieze, Anne Calleja, Loic Ysebaert, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Fontanet Bijou, Anne Quinquenel, Annie Brion, Kamel Laribi
Publikováno v:
61st Annual Meeting and Exposition of the American Society of Hematology
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
Ibrutinib has revolutionized the management of RR CLL in the past 5 years, improving overall survival (OS) over standard chemo-immunotherapies (CIT) in the registration trials HELIOS and RESONATE. Recently, based on these two studies, a score has bee
Publikováno v:
Blood. 132:4979-4979
Background Although significant advances have been made over the past 10 years in the treatment of Immune Thrombocytopenia (ITP), challenges remain in addressing the burden of disease and unmet needs of patients. In rare diseases especially, natural
Autor:
Binal N. Shah, Rasha Raslan, Jin Han, Michel Gowhari, Andrew Srisuwananukorn, Xu Zhang, Robert E. Molokie, Santosh L. Saraf, Victor R. Gordeuk
Publikováno v:
Blood Adv
Sickle cell disease (SCD) is an inherited red blood cell disorder that leads to vaso-occlusion, endothelial damage, and activation of pro-coagulant pathways. Recent studies have demonstrated that thrombotic episodes occur at a 3- to 100-fold higher r
Autor:
Nicholas Finn, Nancy Zhu, Martha Lenis, Lisa Chodirker, Brian Leber, Mary-Margaret Keating, Michelle Geddes, Danielle N. Blunt, Kenneth Rockwood, Jill Fulcher, Robert Delage, Versha Banerji, Karen W.L. Yee, Rena Buckstein, Eve St-Hilaire, Mitchell Sabloff, Liying Zhang, Richard A. Wells, Alexandre Mamedov, Mohamed Elemary, April Shamy, Heather A. Leitch
Publikováno v:
Blood. 132:4850-4850
Background: Health-Related Quality of life (HRQoL) is diminished in patients with myelodysplastic syndrome (MDS). We have previously shown that HRQoL remains stable over time and low hemoglobin, transfusion dependence (TD) and age > 65 years impact Q
Autor:
Wilson I. Gonsalves, Ronald S. Go, Nidhi Tandon, John A. Lust, Amie Fonder, Surbhi Sidana, Angela Dispenzieri, Nelson Leung, Steven R. Zeldenrust, Suzanne R. Hayman, Miriam Hobbs, Shaji Kumar, Martha Q. Lacy, Robert A. Kyle, Stephen J. Russell, Yi L. Hwa, Francis K. Buadi, S. Vincent Rajkumar, David Dingli, Morie A. Gertz, Prashant Kapoor
Publikováno v:
Blood. 128:4627-4627
Introduction High dose chemotherapy and autologous stem cell transplantation (ASCT) is an effective therapy for eligible patients with newly diagnosed systemic AL amyloidosis. Dose attenuated melphalan is used in patients with older age, renal dysfun
Autor:
Leslie A. Andritsos, Natarajan Muthusamy, Qiuhong Zhao, John C. Byrd, Jennifer A. Woyach, Heather Breidenbach, Jeffrey Jones, Amber Gordon, Meixiao Long, Nyla A. Heerema, Caitlin Coombes, Farrukh T. Awan, Amy S. Ruppert
Publikováno v:
Blood. 128:4372-4372
Chronic Lymphocytic Leukemia (CLL) has a varied clinical course; some patients experience a long survival and others succumb to disease in a short time. Clinical factors correlated with either time to first treatment (TFT) and/or overall survival inc
Autor:
Muneer H. Abidi, Andy I. Chen, Tamas Masszi, Auayporn Nadamanee, Veronika Bachanova, Naomi N. H. Hunder, Patrick J. Stiff, Simonetta Viviani, Anna Sureda, Angelo Michele Carella, Dirk Huebner, Jan Walewski, Emily K. Larsen, Jerzy Holowiecki, Craig H. Moskowitz, Dzhelil Osmanov, John W. Sweetenham, Edward Agura
Publikováno v:
Blood. 126:3172-3172
Introduction The AETHERA trial is a phase 3, randomized, placebo-controlled trial (ClinicalTrials.gov #NCT01100502), which evaluated whether post-ASCT consolidation treatment with brentuximab vedotin (BV) could prevent disease progression in Hodgkin